JonesResearch initiated coverage of Achieve Life Sciences with a Buy rating and $20 price target. Achieve is a clinical-stage biopharmaceutical company working to develop and commercialize cytisinicline for tobacco cessation, the analyst tells investors in a research note. The firm believes now is the right time for investors to but Achieve in its transition from a clinical to a commercial biopharmaceutical company. The company is seeking potential non-dilutive funding support for a pivotal trial in e-cigarette cessation, which could see a label expansion for cytisinicline in the first half of 2027, according to Jones.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences reports Q4 EPS (26c), consensus (31c)
- Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, March 28, 2024
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
- Achieve Life Sciences announces data from cytisinicline ORCA program